Optimizing treatment for hypertension has focused on reducing cardiovascular risk through reduction of mean blood pressure (BP) under the basic assumption that lower is better, as long as diastolic BP is sufficient to maintain coronary perfusion. However, antihypertensive therapy as currently practiced does not eliminate all hazards associated with BP elevation. Blood pressure variability (BPV) correlates closely with target-organ damage independent of mean BP and transient increases in BP are also triggers of vascular events. So far, there is no definitive outcome data relating specific reduction in BPV to decline cardiovascular events or death. Thus, the decision whether BPV should be considered a new therapeutic target is left to the clinical judgment of physicians and individualized for each patient. However, new evidence suggests that taking an antihypertensive medication at bedtime significantly affects BPV and lowers the risk of cardiovascular events and death. This strategy may provide a means of individualizing treatment of hypertension according to the circadian BPV of each patient and may be a new option to optimize BP control and reduce risk. 
decreases them by approximately one-third, a meaningful, but clearly suboptimal result. 2) Usual BP, the theoretical true underlying level of blood pressure, is widely considered the main determinant of BP-related vascular risk and of benefit from antihypertensive treatment. The American Heart Association guidelines 3) on measurement BP state that it is generally agreed that conventional clinic readings are a surrogate marker for a patient's true BP and are thought to be the most important component of BP in determining its adverse effects. Like this, clinic BP is used as the primary tool for diagnosis and assessment of hypertension and its severity in clinical practice and in current guidelines. Also, physicians treat hypertension under the basic assumption that lower is better so long as diastolic BP is sufficient to maintain coronary perfusion. 9)
The timing of onset of cardiovascular events strongly parallels the circadian rhythm of BP. Meta-analyses indicate that there is a 40% higher relative risk of acute myocardial infarction, a 29%
increased risk of sudden cardiac death, and a 49% higher relative risk of stroke between 6:00 AM and 12:00 PM compared with the rest of the day though only limited data directly link the early morning surge and the incidence of cardiovascular events. 10, 11) In one prospective study, for each 10 mm Hg increase in baseline early morning systolic BP, the risk of stroke increased by 24%
and the change in BP on rising predicted cardiovascular events independently of age and 24-hour systolic BP mean. 12) However, so far, no clinical trial has been derived to address the relationship between a reduction in the early morning BP and a possible reduction in cardiovascular events.
The non-dipper pattern has been associated with increased risk of cardiac, renal, and vascular target-organ damage compared with the dipper pattern 13) and can be independent of the clinic and 24-hour mean BP values. 14, 15) Additionally, patients with hypertension who exhibit a sleep-time BP increase compared with daytime BP have the worst prognosis for stroke and cardiac events. 14) Recently, the MAPEC study 4) found that a 13% decrease in cardiovascular risk was observed for every 5 mm Hg decline in sleep-time BP, and this risk reduction was independent of changes in other aspects of the circadian BP pattern. Also, reduction in the level of BP during sleep and the difference in sleep-waking BP were the most potent predictors of future events.
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Rothwell et al. 16) reported that visit-to-visit variability in systolic BP was a powerful predictor of stroke and coronary events independent of mean systolic BP in treated hypertensive patients. Also, they showed that residual variability in systolic BP on treatment had a poor prognosis and stable hypertension had a better prognosis than episodic hypertension. Cross-sectional and longitudinal studies have shown that BPV correlates with vascular events in the general population. The Ohasama study, 14) which examined the prognostic significance of increased BPV in a general population in rural Japan, found that increased systolic BPV and decreased heart rate variability were independent predictors of cardiovascular mortality. Similarly, higher levels of short-term visit-to-visit variability in systolic BP were associated with increased all-cause mortality in population based study of US adults. 17) All these results suggest that BPV has an important role in cardiovascular disease and a potentially important impact on the treatment of hypertension.
STRA TEGIES TO REDUCE BLOOD PRESSURE VARIABILITY IN HYPERTENSIVE PATIENTS
Even small reductions in BP for short periods substantially improve cardiovascular outcomes. However, more recent evidence has emphasized the importance of optimal BP control, particularly on patients with high cardiovascular risk because the results are still unsatisfactory: 62% of cerebrovascular disease and 49% of ischemic heart disease can be attributed to suboptimal BP treatment. 18) BPV is not only associated with the severity of targetorgan damage but also has a prognostic value for the subsequent target-organ damage in hypertensive patients. 19, 20) These findings suggest that buffering the enhanced BPV commonly found in hypertensive patients may be an equally important target of antihypertensive treatment. Optimal BP control requires strategies that lower BP consistently and fully throughout a 24-hour period, maintain the normal circadian pattern of BP, do not increase BPV, and optimize the patient's compliance.
21)
The early morning surge in blood pressure is mediated in part by the sympathetic nervous system and through the renin-angiotensin-aldosterone system (RAAS). Otherwise, pathophysiology leading to a loss of decline in sleep-time BP is probably mediated by RAAS activation and volume excess.
Therefore, the pathophysiology of the circadian BPV allows us to consider the potential for blockade of systems leading to this abnormal circadian BP profile. 6) In 1987, Parati et al. 19) showed that for nearly any level of mean 24-hour BP assessed intra-arterially, subjects with high BP variability had more severe target-organ damage, an observation confirmed by long-term follow-up in the same patients. Moreover, evidence suggests that drug-induced BPV can also be deleterious.
Short-acting antihypertensive agents can cause BPV over a 24- simply by increasing the dose of a short-acting agent to prolong its action, because the patient would be exposed to the risk of an unacceptably low BP during the time of peak drug effect and the resulting BPV over 24-hour would be greatly amplified. In this regards, a hypertensive patient with dipper pattern should, at least a priori, probably be treated using a strategy consisting of a single morning dosing of an antihypertensive medication (alone or in combination) that is known to have a high therapeutic coverage.
On the other hand, a hypertensive with non-dipper pattern will need to add a second dose or additional medication at bedtime, or even shift to evening dosing in order to control BP and to normalize the altered 24-hour BP pattern.
OUTCOMES OF NORMALIZATION OF CIRCADIAN BLOOD PRESSURE VARIABILITY
Indeed, normalization of the circadian BP pattern towards a more dipper pattern has already been associated with a significant decrease in plasma fibrinogen, decrease in urinary albumin excretion, better metabolic profile, and better BP control. 
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